VCN Biosciences is a biotechnology startup founded in 2009 with a focus on pioneering advanced tumor treatments. The company specializes in the research and development of new treatments for tumors, utilizing oncolytic virus technology. In July 2012, VCN Biosciences secured its last investment in a funding round led by Grifols, demonstrating strong support from established players in the industry. With a commitment to innovation in the biotechnology sector, VCN Biosciences is positioned to make a significant impact in the development of cutting-edge tumor treatments.
VCN Biosciences
Pioneering advanced tumor treatments through innovative oncolytic virus technology.
Founded 2009
11-50 employees
Biotechnology
General Information
Company Name
VCN Biosciences
Founded Year
2009
Employees
11-50
Industries
Biotechnology
Social
BounceWatch is an independent company data service, not affiliated with VCN Biosciences. To contact VCN Biosciences, visit vcnbiosciences.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does VCN Biosciences compare?
A PDF of VCN Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting VCN Biosciences soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is VCN Biosciences on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
About VCN Biosciences
Business keywords: Oncolytic Virus, Tumor Treatment, VCN Biosciences, Innovative Technology, Research and Development, Advanced Therapy, Biosciences, Cancer Treatment, Medical Innovation, Cancer Research
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Funding Round | Undisclosed | 1 |
Grifols
|
09 Jul 2012 |
VCN Biosciences Alternatives & Competitors
View All Alternatives
VCN Biosciences vs
VYROBIO
Brazil
Developing next-generation viral immunotherapies to treat aggressive, fast-growing forms of CNS tumo...
Seed
9 employees
Biotechnology
VCN Biosciences vs
Advancing the future of tumor treatment through innovative research and application in immunotherapy...
Seed
11-50 employees
Biotechnology
VCN Biosciences vs
Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art...
Series A
Biotechnology, Life Sciences
FAQ About VCN Biosciences
Pioneering advanced tumor treatments through innovative oncolytic virus technology.
VCN Biosciences was founded in 2009.
VCN Biosciences operates in Biotechnology. Its work centres on Oncolytic Virus, Tumor Treatment, VCN Biosciences and Innovative Technology.
VCN Biosciences has approximately 11-50 employees.
VCN Biosciences has completed 1 funding round.
Top alternatives and competitors to VCN Biosciences include VYROBIO, Immupeutics Medicine, Huasaiboman Medical Cell Biology, OncoMyx Therapeutics, Farcast Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VCN Biosciences and VYROBIO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for VCN Biosciences, https://bouncewatch.com/company/vcn-biosciences, updated 2 January 2025. When citing, please name BounceWatch and link this page.
